Home/Pipeline/MP0533

MP0533

Acute Myeloid Leukemia (AML)

Phase 1/2aActive

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Phase 1/2a

Status

Active

Company

Molecular Partners

About Molecular Partners

Molecular Partners is a mission-driven biotech founded in 2004, focused on transforming the lives of patients with serious diseases through its innovative DARPin platform. The company has achieved clinical validation for its technology and is advancing a pipeline of next-generation oncology candidates, including tetra-specific T-cell engagers and logic-gated Switch-DARPins. Its strategy combines deep in-house R&D expertise with strategic collaborations to build a broad portfolio targeting high-unmet-need cancers.

View full company profile

Therapeutic Areas

Oncology

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
Mipletamig (APVO436)	Aptevo Therapeutics	Phase 1/2	Active
lomonitinib	Lomond Therapeutics	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
AB8939	AB Science	Phase 1	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 1	Active
NC525	NextCure	Preclinical	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)
HC-7366	HiberCell	Phase 1b	Active - Monotherapy & in combination with venetoclax and azacitidine
Prexigebersen (BP1001)	Bio-Path Holdings	Phase 2	Active